Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Enlivex Therapeutics Ltd. (ENLV) had Normalized Pre-Tax Income of $-15.01M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-15.01M |
|
-- |
|
-- |
|
$15.89M |
|
$-15.89M |
|
$0.87M |
|
$-15.01M |
|
|
Normalized Pre-Tax Income |
$-15.01M |
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.89M |
|
$-15.34M |
|
20.51M |
|
20.51M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$25.99M |
|
$0.62M |
|
$1.69M |
|
$27.69M |
|
$3.80M |
|
-- |
|
$0.30M |
|
$4.10M |
|
$23.59M |
|
$23.59M |
|
$23.59M |
|
23.65M |
|
| Cash Flow Statement Financials | |
$-13.01M |
|
$9.06M |
|
$6.45M |
|
$1.23M |
|
$3.73M |
|
$2.50M |
|
$2.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.84 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.93M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-63.65% |
|
-63.65% |
|
-54.23% |
|
-63.65% |
|
$1.00 |
|
$-0.63 |
|
$-0.63 |
|